Close Menu

NEW YORK (GenomeWeb) – Biocept announced today that it is initiating a new study in collaboration with MedStar Georgetown University Hospital, using its liquid biopsy technology to evaluate drug resistance biomarkers in patients being treated with EGFR inhibitors or chemotherapy for non-small cell lung cancer.

Conducted at the Georgetown Lombardi Comprehensive Cancer Center under the direction of Professor Giuseppe Giaccone, the study will use Biocept's combined circulating tumor cell and cell-free tumor DNA platform to detect biomarkers such as EGFR, MET, ALK, and BRAF.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

Dec
11
Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.